NCT05361031已完成1 期
Single Center, Open Label, Repeat Intramuscular Administration, 270 Days, Phase I/2a Clinical Trial to Evaluate Safety, Tolerability of Investigational Product (Engensis: VM202) With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Safety of Intramuscular (IM) Injections of Engensis in Participants
研究概览
简要总结
To assess the safety and tolerability of the investigational product Engensis (VM202) injected in the weakened lower limb muscles of CMT1A patients
详细描述
There are no therapeutic agents for CMT to date. Attempts were made to develop therapeutic agents, but efficacy could not be demonstrated in clinical studies. Most of the attempted developments for therapeutic agents targeted alleviating the symptoms of CMT1A by regulating the expression of PMP22. This study will use Engensis (VM202), which is a DNA plasmid that contains novel genomic cDNA hybrid human HGF coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723. HGF has been thought of as an angiogenic factor, but it has been recently identified as serving the role of a neurotrophic factor. Moreover, it has been reported that it can contribute to muscle tissue regeneration by targeting on muscles. Considering the pathologic mechanism of CMT, the biological activity of HGF helps peripheral nerve regeneration, relieves muscle atrophy, and reduces pain, so it is highly likely to show a therapeutic effect for CMT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females ≥ 19 years of age and ≤ 65 years of age
- •Patients with confirmed diagnosis of CMT1A by genetic testing
- •Patients with mild to moderate severity assessed by Charcot Marie Tooth Neuropathy Score version 2 (CMTNS v2) with a score > 2 and ≤ 20
- •Individuals with lower limb muscle weakness with minimum dorsiflexion or more
- •Individuals who voluntarily consented to participate in this study and signed the IRB approved informed consent form after listening to a description on the characteristics of this clinical study prior to all screening tests
- •Individuals who can comply with the requirements in the clinical study
- •In case of females of child bearing potential, those who test negative in a urine or serum pregnancy test at screening
- •Individuals who practice medically approved contraceptive methods throughout the clinical study
排除标准
- •Patients with significant respiratory, circulatory, renal, gastrointestinal, hepatic, endocrine, hematologic, psychiatric disorders or other severe diseases, or alcohol or drug addiction who may develop safety issues or cause confusion in the interpretation of the clinical study results as determined by the principal investigator
- •Patients with other neuromuscular diseases or neuropathy-inducing factors: Patients with chronic alcohol addiction, undergoing anticancer chemotherapy, or taking neurotoxic drugs
- •Patients diagnosed with diabetes
- •Patients diagnosed with inflammatory bowel disease
- •Patients with a history of stroke or cerebral ischemic attack within 12 months prior to the screening date
- •Patients with a history of coronary artery disease, such as myocardial infarction and unstable angina pectoris, within 12 months prior to the screening date
- •Morbidly obese patients with body mass index (BMI) ≥ 37
- •Patients who underwent orthopedic surgery (corrective surgery for bone and ligament, artificial joint implantation, osteosynthesis, osteotomy, arthroscopic surgery) in the lower limbs within 6 months prior to the screening date
- •Patients who may be affected by the muscle strength measurement test due to ankle contracture or surgery
- •Patients with uncontrolled hypertension (if systolic blood pressure is ≥ 160 mmHg or diastolic blood pressure is ≥ 100 mmHg at screening)
- •Patients or patient's immediate family members (parents, siblings, offspring) with a history of malignant tumors within the last 5 years prior to the screening date, excluding basal cell carcinoma or squamous cell carcinoma that occurs on the skin (if it is determined that there is no possibility of relapse after resection), or with a family history of familial adenomatous polyposis (FAP) or hereditary nonpolyposis colorectal cancer (HNPCC)
- •Patients who have not completed a national cancer screening program applicable to their sex and age (if it cannot be confirmed that the relevant test was received at a national cancer screening center or a recognized screening center)
- •However, if it is confirmed that the relevant test was received at a national cancer screening center or a recognized screening center during the screening period, and that the results were within normal range, the patients may participate in the clinical study.
- •Common to males and females: If a patient is ≥ 50 years of age, the results of a colonoscopy within 5 years prior to the screening must be determined as being within normal range, and if adenomatous polyps are evident, the results of a colonoscopy within 1 year must be determined as being within normal range (inflammatory polyps or hyperplastic polyps are included in the normal range). If a patient is ≥ 40 years of age, the results of a gastroscopy within 2 years prior to the screening must be within normal range. If a patient is ≥ 54 years of age and has a 30 pack-year history of smoking or more, the results of a low-dose chest CT within 2 years prior to the screening must be within normal range. In case of liver cancer, carriers of hepatitis B or hepatitis C virus and patients with hepatic cirrhosis fall under the exclusion criteria.
- •Females: For females ≥ 40 years of age, normal range findings must be confirmed in a mammogram within 2 years. For females ≥ 20 years of age, normal range findings must be confirmed in a Pap smear within 2 years.
- •Patients diagnosed with active pulmonary tuberculosis
- •Patients with HBV or HCV
- •Patients who test positive in human immunodeficiency virus (HIV) antibody test
- •Patients in an immunosuppressive state due to treatments such as immunosuppressants, chemotherapy, and radiotherapy
- •Patients with a history of mental disease within 6 months prior to the screening date, which may interfere with participation in the study
- •Patients who must take medications, that are known to have significant drug interactions within 14 days after the first administration of the investigational product or deemed unsuitable by the investigator's judgment
- •Individuals who participated in another clinical study within 6 months before the time of screening
- •Individuals who have shown significant adverse events such as hypersensitivity reactions to the investigational product
- •Pregnant or breastfeeding females
- •Other individuals determined ineligible by the principal investigator to participate in the clinical study due to other reasons including clinical laboratory test results
研究组 & 干预措施
Engensis (VM202)
Experimental
56 (ea) 0.25mg (0.5 mL) injections in each of the left and right lower limbs on Days 0, 14, 90, and 104.
干预措施: Engensis (VM202) (Biological)
结局指标
主要结局
Safety of Intramuscular (IM) Injections of Engensis in Participants
时间窗: Day 0 visit to the Day 270 visit
Frequency and percentage of treatment-emergent adverse events (TEAEs) and serious adverse events after injections, injection site reactions, vital sign, and clinically significant laboratory values for Engensis.
次要结局
- Evaluation of Severity of Disease Changes Following Engensis Injections - Charcot Marie Tooth Neuropathy Score Version 2(Day 0 and Day 270)
- Evaluation of Patient's Neurological Disability - Functional Disability Score(Day 0, 90, 180 and Day 270)
- Evaluation of the Activity Level of Patients With Peripheral Neuropathy Using the Overall Neuropathy Limitation Score Leg Scale(Day 0, 90, 180 and Day 270)
- Evaluation of Patient's Walking Ability - Change From Baseline in the 10-Meter Walk Test(Day 0, 90, 180 and Day 270)
- Changes in Fatty Infiltration Level of Lower Limb Muscles(Day 0 and Day 270)
- Change From Baseline in Nerve Conduction Velocity at Day 270(Day 0 and Day 270)
- Numbers of Participants With and Without Hepatocyte Growth Factor Antibody Generation in the Body at Baseline (Day 0) and Day 270.(Day 0 and Day 270)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety Study of VM202 to Treat Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisNCT02039401Helixmith Co., Ltd.18
已完成
1 期
Gene Therapy for Painful Diabetic NeuropathyNCT01002235Helixmith Co., Ltd.12
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of AgeRespiratory Syncytial VirusesRespiratory Tract InfectionsNCT03303625Janssen Vaccines & Prevention B.V.48
已完成
2 期
A Dose Finding Study of VN-0200Respiratory Syncytial Virus InfectionsNCT05547087Daiichi Sankyo342
已完成
1 期
Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric ParticipantsInfluenza InfectionNCT02367885Takeda99